Literature DB >> 16803885

Kinetic dependence to HIV-1 entry inhibition.

H Kirby Steger1, Michael J Root.   

Abstract

Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41 trimer-of-hairpins. A designed protein, 5-Helix, targets the C-terminal region of the gp41 ectodomain, disrupting trimer-of-hairpins formation and blocking viral entry. Here we show that the nanomolar inhibitory potency of 5-Helix (IC50 approximately 6 nm) is 4 orders of magnitude larger than its subpicomolar binding affinity (K(D) approximately 0.6 pm). This discrepancy results from the transient exposure of the 5-Helix binding site on gp41. As a consequence, inhibitory potency is determined by the association rate, not by binding affinity. For a series of 5-Helix variants with mutations in their gp41 binding sites, the IC50 and K(D) values poorly correlate. By contrast, an inverse relationship between IC50 values and association rate constants (k(on)) extends for over 2 orders of magnitude. The kinetic dependence to inhibition places temporal restrictions on an intermediate state of HIV-1 membrane fusion and suggests that access to the C-terminal region of the gp41 ectodomain is largely free from steric hindrance. Our results support the importance of association kinetics in the development of improved HIV-1 fusion inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803885     DOI: 10.1074/jbc.M601457200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Authors:  Min Zhuang; Wei Wang; Christopher J De Feo; Russell Vassell; Carol D Weiss
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

2.  Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Authors:  Lifeng Cai; Chungen Pan; Liang Xu; Yuan Shui; Keliang Liu; Shibo Jiang
Journal:  FASEB J       Date:  2011-11-15       Impact factor: 5.191

3.  Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

Authors:  Brett D Welch; J Nicholas Francis; Joseph S Redman; Suparna Paul; Matthew T Weinstock; Jacqueline D Reeves; Yolanda S Lie; Frank G Whitby; Debra M Eckert; Christopher P Hill; Michael J Root; Michael S Kay
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

4.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

5.  Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.

Authors:  Hillel Haim; Israel Steiner; Amos Panet
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  Potent D-peptide inhibitors of HIV-1 entry.

Authors:  Brett D Welch; Andrew P VanDemark; Annie Heroux; Christopher P Hill; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

7.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Authors:  John J Dwyer; Karen L Wilson; Donna K Davison; Stephanie A Freel; Jennifer E Seedorff; Stephen A Wring; Nicolai A Tvermoes; Thomas J Matthews; Michael L Greenberg; Mary K Delmedico
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-19       Impact factor: 11.205

8.  Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Authors:  Kelly Champagne; Akira Shishido; Michael J Root
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

Review 9.  HIV entry: a game of hide-and-fuse?

Authors:  Gregory B Melikyan
Journal:  Curr Opin Virol       Date:  2013-11-01       Impact factor: 7.090

10.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.